Get the Stockscreener App
1.435
2.50%
0.035
Acumen Pharmaceuticals Inc stock is traded at $1.435, with a volume of 157.89K.
It is up +2.50% in the last 24 hours and up +23.71% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$1.40
Open:
$1.4
24h Volume:
157.89K
Relative Volume:
0.37
Market Cap:
$86.62M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-1.2813
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
+2.50%
1M Performance:
+23.71%
6M Performance:
+2.50%
1Y Performance:
-46.05%
1-Day Range:
$1.3701
$1.47
1-Week Range:
$1.29
$1.47
52-Week Range:
$0.8551
$3.36
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
925-368-8508
Address
427 PARK ST., CHARLOTTESVILLE
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.43 | 82.38M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.97 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.42 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.95 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.26 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.12 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Using economic indicators to assess Acumen Pharmaceuticals Inc. potentialMarket Opportunity Tracker for Swing Traders - Newser
Acumen Pharmaceuticals Inc. stock momentum explainedFree Daily Chart Pattern Stock Forecast - Newser
How to build a dashboard for Acumen Pharmaceuticals Inc. stockWeekly Price Target Forecast and Alerts - Newser
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 - The Manila Times
Acumen Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Alzheimer's Drug Development - Stock Titan
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewswire Inc.
Exit strategy if you’re trapped in Acumen Pharmaceuticals Inc.Short-Term Support and Resistance Forecast - Newser
Top Risks to Consider Before Buying Acumen Pharmaceuticals Inc. StockDaily Stock Forecast Powered by AI Tools - Newser
What makes Acumen Pharmaceuticals Inc. stock price move sharplyWealth Accumulation Outlook for Safe Investors - Newser
Analyzing drawdowns of Acumen Pharmaceuticals Inc. with statistical toolsFree Risk Adjusted Technical Entry Plan - Newser
How volatile is Acumen Pharmaceuticals Inc. stock compared to the marketAchieve rapid portfolio appreciation today - Jammu Links News
What drives Acumen Pharmaceuticals Inc. stock priceConsistently outstanding ROI - Jammu Links News
How many analysts rate Acumen Pharmaceuticals Inc. as a “Buy”Achieve breakthrough profits with expert advice - Jammu Links News
How strong is Acumen Pharmaceuticals Inc. company’s balance sheetAccess powerful market insights for free - Jammu Links News
What institutional investors are buying Acumen Pharmaceuticals Inc. stockInvest with confidence backed by data - Jammu Links News
What are Acumen Pharmaceuticals Inc. company’s key revenue driversMassive profits - Jammu Links News
Why is Acumen Pharmaceuticals Inc. stock attracting strong analyst attentionRecord-breaking capital gains - Jammu Links News
Is Acumen Pharmaceuticals Inc. a growth stock or a value stockMaximize portfolio value with timely trades - Jammu Links News
How Acumen Pharmaceuticals Inc. stock performs during market volatilityControlled Entry Strategy With Safety Analytics - Newser
What catalysts could drive Acumen Pharmaceuticals Inc. stock higher in 2025Maximize returns with strategic stock selection - Jammu Links News
How to monitor Acumen Pharmaceuticals Inc. with trend dashboardsEquity Signal Recap With Long-Term Summary - Newser
Acumen Pharmaceuticals’ Promising Alzheimer’s Study: A Potential Game-Changer? - TipRanks
When is Acumen Pharmaceuticals Inc. stock expected to show significant growthWealth Building Picks That Work - Jammu Links News
Using Python tools to backtest Acumen Pharmaceuticals Inc. strategiesPortfolio Review Summary with Five-Year Outlook - Newser
Has Acumen Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewStock Entry Points Based on Technicals - Newser
Acumen Pharmaceuticals Inc. Moves Into Bullish Territory Based on MACDAlpha Focused Technical Trade Signals Gain Attention - metal.it
Momentum Screeners Rank Acumen Pharmaceuticals Inc. in Top 5 TodayDaily Chart Pattern Stock Forecast Shows Bullish Setup - beatles.ru
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025 - The Manila Times
40% Trial Cost Cut: Acumen's New Alzheimer's Drug Shows Superior Target Selectivity | ABOS Stock News - Stock Titan
Are Bears Losing Grip on Acumen Pharmaceuticals Inc.Weekly Stock Opportunity Radar Scanner Activated - metal.it
What is Acumen Pharmaceuticals Inc. company’s growth strategyAchieve rapid returns with smart investment plans - Jammu Links News
How does Acumen Pharmaceuticals Inc. compare to its industry peersAchieve breakthrough financial results - Jammu Links News
What is the dividend policy of Acumen Pharmaceuticals Inc. stockRapidly expanding wealth - Jammu Links News
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
0.36%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):